Postoperative adjuvant chemotherapy with 1-hexylcarbamoyl-5-fluorouracil in patients with colorectal cancer and at a high risk for recurrence

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4629-4634

  Maehara, Yoshihiko ^a   Sugimachi, Keizo ^a   Ogawa, Michio ^b   Kakegawa, Teruo ^c   Tomita, Masao ^d   Akiyoshi, Tsuyoshi ^e  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

1 hexylcarbamoyl 5 fluorouracil; 5 fluorouracil; Colorectal cancer; Postoperative chemotherapy; Prognosis; Recurrence

Indexed keywords

CARMOFUR; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL TIME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECTAL NEOPLASMS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0032408578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hoshi A, Iigo M, Yoshida M, Kuretani K: Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration. Gann (Jpn J Cancer Res) 66: 673-674, 1975.
2. Hoshi A, Iigo M, Nakamura A, Yoshida M, Kuretani K: Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Gann (Jpn J Cancer Res) 67: 725-731, 1976.
3. Hoshi A, Yoshida M, Inomata M, Iigo M, Ando N, Kuretani K: Antitumor activity of metabolites of 1-hexylcarbamoyl-5- fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro. J Pharm Dyn 3: 478-481, 1980.
4. HCFU Clinical Study Group: Absorption and excretion of a new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patients. Jpn J Clin Oncol 10: 83-92, 1980.
5. Kobari T, Tan K, Kumakura M, Watanabe S, Shirakawa I, Kobayashi H, Ujiie A, Miyama Y, Namekawa H, Yamamoto H: Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats. Xenobiotica 8: 547-556, 1978.
6. Iigo M, Hoshi A, Nakamura A, Kuretani K: Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother Pharmacol 1: 203-208., 1978
7. Iigo M, Hoshi A, Nakamura A, Kuretani K: Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma. J Pharm Dyn 1: 49-54, 1978.
8. Okabayashi K, Koyama Y, Maruyama K, Okazaki N, Sakano T, Ise T: Clinical trials of a new anticancer drug, 1-hexylcarbamoyl-5-fluorouracil. Jpn J Clin Oncol 9: 35-40, 1979.
9. Koyama Y: 1-hexylcarbamoyl-5-fluorouracil (HCFU) -a masked 5-fluorinated pyrimidine. Cancer Treat Rev 8: 147-156, 1981
10. Gron P, Heinonen E, Kumpulainen E, Lansimies H, Lantto A, Salmi R, Pyrhonen S, Numminen S: Oral carmofur in advanced gastrointestinal cancer. Am J Clin Oncol (CCT) 13: 477-479, 1990.
11. Maehara, Y, Anai H, Kusumoto H, Kusumoto T, Sugimachi K: Colorectal carcinoma in vitro is more sensitive to 1- hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil. Dis Colon Rectum 31: 62-67, 1988.
12. Davis HL: Chemotherapy of large bowel cancer. Cancer 50: 2638-2646, 1982.
13. Petrelli NJ, Mittelman A: An analysis of chemotherapy for colorectal carcinoma. J Surg Oncol 25: 201-206, 1984.
14. Buroker T, Padilla F, Groppe C, Guy G, Quagliana J, McCracken J, Heilbrun L: Phase II evaluation of ftorafur in previously untreated colorectal cancer. Cancer 44: 48-51, 1979.
15. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N: Mitomycin C plus carmofur (HCFU) adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma (Interim report) Jpn J Surg 17: 354-361, 1987.